Swiss National Bank Invests $6.27 Million in Enovis Co. (NYSE:ENOV)

Swiss National Bank bought a new position in Enovis Co. (NYSE:ENOVGet Rating) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 114,000 shares of the company’s stock, valued at approximately $6,270,000. Swiss National Bank owned about 0.21% of Enovis at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. M&T Bank Corp bought a new stake in shares of Enovis in the second quarter worth about $137,000. Boenning & Scattergood Inc. bought a new stake in shares of Enovis in the second quarter worth about $210,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enovis in the second quarter worth about $261,000. TAGStone Capital Inc. bought a new stake in shares of Enovis in the second quarter worth about $288,000. Finally, Citadel Investment Advisory Inc. bought a new stake in shares of Enovis in the second quarter worth about $288,000. 89.40% of the stock is owned by institutional investors.

Enovis Price Performance

Shares of NYSE:ENOV opened at $54.99 on Thursday. Enovis Co. has a 1 year low of $43.88 and a 1 year high of $151.63. The business has a 50 day simple moving average of $49.81 and a two-hundred day simple moving average of $55.28. The firm has a market capitalization of $2.98 billion, a PE ratio of 114.56, a price-to-earnings-growth ratio of 1.15 and a beta of 2.03.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group started coverage on Enovis in a report on Monday, September 12th. They issued a “buy” rating and a $67.00 target price on the stock. Canaccord Genuity Group started coverage on Enovis in a research note on Monday, September 12th. They set a “buy” rating and a $67.00 price objective on the stock. Jefferies Financial Group started coverage on Enovis in a research note on Wednesday, October 12th. They set a “buy” rating and a $60.00 price objective on the stock. Wells Fargo & Company reduced their price objective on Enovis from $60.00 to $53.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 26th. Finally, TheStreet cut Enovis from a “c” rating to a “d” rating in a research note on Wednesday, November 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $63.50.

Insider Buying and Selling at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total transaction of $3,679,838.18. Following the completion of the transaction, the executive vice president now owns 75,731 shares in the company, valued at $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.30% of the company’s stock.

Enovis Company Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Recommended Stories

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOVGet Rating).

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.